{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"304"},{"groupId":"OG001","value":"376"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"77"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"316"},{"groupId":"OG001","value":"456"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"165"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"34"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"37"}],"units":"Participants"}],"description":"Number of treated patients with at least one adverse event reported (assessed by Common Terminology Criteria for Adverse Events (version 4.0))","groups":[{"description":"Patients receive paclitaxel IV over 3 hours or docetaxel IV over 1 hour and carboplatin over 30 minutes on day 1. Treatment repeats every 21 days. Patients are not in secondary cytoreductive surgery portion of study.\n\nCarboplatin: Given IV\n\nDocetaxel: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPaclitaxel: Given IV\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG000","title":"Arm I (no Surgery; Carboplatin and Paclitaxel)"},{"description":"Patients receive chemotherapy as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days. Patients are not in secondary cytoreductive surgery portion of study.\n\nBevacizumab: Given IV\n\nCarboplatin: Given IV\n\nDocetaxel: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPaclitaxel: Given IV\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG001","title":"Arm II (no Surgery; Carboplatin, Paclitaxel and Bevacizumab)"},{"description":"Patients receive paclitaxel IV over 3 hours or docetaxel IV over 1 hour and carboplatin over 30 minutes on day 1. Treatment repeats every 21 days. Patients receive secondary cytoreductive surgery.\n\nCarboplatin: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPaclitaxel: Given IV\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG002","title":"Arm III (Surgery; Carboplatin and Paclitaxel)"},{"description":"Patients receive paclitaxel IV over 3 hours or docetaxel IV over 1 hour and carboplatin over 30 minutes on day 1. Treatment repeats every 21 days. Patients receive secondary cytoreductive surgery.\n\nBevacizumab: Given IV\n\nCarboplatin: Given IV\n\nDocetaxel: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPaclitaxel: Given IV\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG003","title":"Arm IV (Surgery; Carboplatin, Paclitaxel and Bevacizumab)"},{"description":"Patients receive carboplatin as in arm I. Patients receive gemcitabine. Treatment repeats every 21 days. Patients do not receive secondary cytoreductive surgery.\n\nCarboplatin: Given IV\n\nGemcitabine Hydrochloride: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG004","title":"Arm V (no Surgery; Carboplatin and Gemcitabine)"},{"description":"Patients receive carboplatin as in arm I and bevacizumab IV over 30-90 minutes on day 1. Patients receive gemcitabine. Treatment repeats every 21 days. Patients do not receive secondary cytoreductive surgery.\n\nBevacizumab: Given IV\n\nCarboplatin: Given IV\n\nGemcitabine Hydrochloride: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG005","title":"Arm VI (no Surgery; Carboplatin, Gemcitabine and Bevacizumab))"},{"description":"Patients receive carboplatin as in arm I. Patients receive gemcitabine. Treatment repeats every 21 days. Patients receive secondary cytoreductive surgery.\n\nCarboplatin: Given IV\n\nGemcitabine Hydrochloride: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG006","title":"Arm VII (Surgery; Carboplatin and Gemcitabine)"},{"description":"Patients receive carboplatin as in arm I and bevacizumab IV over 30-90 minutes on day 1. Patients receive gemcitabine. Treatment repeats every 21 days. Patients receive secondary cytoreductive surgery.\n\nBevacizumab: Given IV\n\nCarboplatin: Given IV\n\nGemcitabine Hydrochloride: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG007","title":"Arm VIII (Surgery; Carboplatin, Gemcitabine and Bevacizumab))"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Eligible and treated participants","reportingStatus":"POSTED","timeFrame":"During treatment period and up to 100 days after stopping the study treatment, a median duration of 82.5 months","title":"Summary of Adverse Events (CTCAE Version 4.0)","type":"SECONDARY","unitOfMeasure":"Participants"}